Form 4: REGENXBIO Director Allan M. Fox Reports Stock and Option Transactions

Director Allan M. Fox reported the acquisition of common stock and stock options in REGENXBIO Inc. on May 31, 2024.

Summary

• On May 31, 2024, Allan M. Fox, a director of REGENXBIO Inc., acquired 4,790 shares of common stock related to a restricted stock unit award.
• These shares will vest on May 1, 2025, contingent upon continuous service to the Issuer.
• Fox also acquired 24,454 stock options with an exercise price of $14.35, vesting in 12 equal monthly installments starting May 31, 2024, and expiring on May 31, 2034.
• Following these transactions, Fox directly owns 11,286 shares of common stock.
• Fox also indirectly owns 722,485 shares through AMF Family Gift Trust LLC, 315,000 shares through AMF Gift Trust LLC, 315,000 shares through HBF Gift Trust LLC, and 1,529,981 shares through Quaker Gray LLC.
• Fox disclaims beneficial ownership of shares held by the trusts and Quaker Gray LLC except to the extent of his indirect pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports routine insider transactions without indicating any specific positive or negative outlook for the company.

Positives

• The acquisition of stock and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The restricted stock units will vest on May 1, 2025, and the stock options will vest in 12 equal monthly installments following May 31, 2024, both subject to continuous service.

Management Comments

• The reporting person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company.

Comparison to Industry Standards

• Insider transactions are a common occurrence in publicly traded companies like REGENXBIO.
• Comparing the size and frequency of these transactions to peers such as BioMarin Pharmaceutical or Sarepta Therapeutics could provide additional context.
• The vesting schedules and exercise prices of the options are typical for executive compensation packages in the biotech industry.

Stakeholder Impact

• The transactions could have a minor impact on shareholders by slightly diluting the stock if the options are exercised in the future.
• Employees who are also option holders may view this as a positive sign of management's confidence.

Key Dates